Table of Contents

    Topic review

    Point-of-Care C-Reactive Protein Testing

    Subjects: Others
    View times: 81

    Definition

    C-reactive protein (CRP) point-of-care test(-ing) (POCT) is one of the top strategies targeted at clinicians to reduce antibiotic prescribing, and it is increasingly being promoted to enhance antibiotic stewardship. CRP-POCT can guide antibiotic prescribing for (lower and upper) RTIs in primary care can reduce antibiotic prescribing at index consultations especially if cut-off guidance is provided.

    1. Introduction

    C-reactive protein (CRP) point-of-care testing (POCT) is increasingly being promoted to reduce diagnostic uncertainty and enhance antibiotic stewardship. In primary care, respiratory tract infections (RTIs) are the most common reason for inappropriate antibiotic prescribing, which is a major driver for antibiotic resistance.

    Acute respiratory tract infections (RTIs) are among the most common reasons for patient encounters in primary care and for inappropriate antibiotic prescribing, which is a major driver for antibiotic resistance (ABR) [1][2][3][4][5]. RTIs are predominantly of viral aetiology and self-limiting in most otherwise healthy individuals. Evidence from systematic reviews and other studies shows that most patients suffering from acute RTIs, such as sore throat, acute sinusitis, pharyngitis, rhinosinusitis, otitis media, and acute bronchitis, do not benefit from antibiotic therapy [6][7][8]. International clinical practice guidelines consequently advise against routine treatment of uncomplicated RTIs with antibiotics [9]. The vast majority of patients with these infections, however, receive an antibiotic prescription for systemic use after seeking medical attention from their primary care physician [4][9].

    Inappropriate use of antibiotics is linked to the development of drug-resistant bacteria and increases the incidence of adverse events, re-consultations, and complications and subsequently increases healthcare costs [3][10][11][12][13][14]. Moreover, the rates of antibiotic prescribing have been directly associated with the rates of ABR at the individual, community, and national levels [3][4]. The reduction of antibiotic prescribing for acute RTIs could thus help to decrease ABR. If no effective actions are taken ABR could become the leading cause of death, surpassing cancer [15].

    C-reactive protein (CRP) point-of-care test(-ing) (POCT) is one of the top strategies targeted at clinicians to reduce antibiotic prescribing, and it is increasingly being promoted to enhance antibiotic stewardship [16]. It has been demonstrated that uncertainty about the diagnosis of infection can lead to inappropriate antibiotic prescribing, overuse of resources, and disease complications [17][18][19]. With CRP as a biomarker of systematic inflammation, however, CRP-POCT enables clinicians to discern bacterial infections from other inflammatory disorders and helps them to identify the patients who benefit the most from antibiotics [20]. The robustness and accuracy of CRP-POCT compared with laboratory testing have been demonstrated by diagnostic studies [21]. CRP-POCT has also been integrated into some clinical guidelines as part of the assessment for RTIs to reduce diagnostic uncertainty and to aid prescribing decisions [22][23].

    2. Functions of CRP-POCT

    Based on evidence of moderate to high- quality, the results demonstrate that CRP-POCT can reduce immediate (at index consultations) antibiotic prescribing in patients presenting to primary care with upper and lower RTIs. CRP-POCT in combination with CRP (cut-off) guidance effectively reduced immediate antibiotic prescribing in children and enhanced the effect already gained by performing CRP-POCT in adults. Although there was a significant increase in the rates of re-consultation (NNTH = 27) within 30 days of testing, an NNTnet of 11 indicates that the benefit in reducing antibiotic prescribing (NNTB = 8) outweighs the harm when adding CRP-POCT to usual care. Most of the evidence originates from the GP setting where, in addition to the (hospital) outpatient care setting, CRP-POCT appears most effective in reducing antibiotic prescribing. We found no significant effect of CRP-POCT in the rates of clinical recovery, resolution of symptoms, hospital admissions, referrals to secondary care, or in the ordering of further investigations. One study reported no deaths. Limited evidence showed that CRP-POCT did not significantly reduce antibiotic prescribing at any point during 28-days of follow-up (n = 7) and that antibiotic prescribing at the index consultation was still lower in the GPs intervention at 12 months (n = 1).

    CRP-POCT is a simple test that is being widely used in many countries to help clinicians identify whether patients with RTIs need antibiotics and to consequently reduce unnecessary antibiotic prescribing. The test can be performed within five minutes, helping clinicians with rapid decision-making during the consultation. Considering the global importance of antimicrobial resistance and its association with the extent of antibiotic consumption, compared with previous reviews [24][25], we found a slowly increasing volume of evidence from empirical research (n = 13 RCTs) mostly published in English. The studies were carried out mostly in high-income countries, predominantly in general practices in the northern European setting, mainly the Netherlands. The evidence represents populations of all ages (range: 0-90), the majority of whom were young adults (mean age: 26.4, SD 15.0), mostly women (56%), with signs and symptoms of RTIs.

    3. Conclusions

    So far, evidence of moderate to high quality shows that compared with usual care, using CRP-POCT to guide antibiotic prescribing for (lower and upper) RTIs in primary care can reduce antibiotic prescribing at index consultations especially if cut-off guidance is provided. This reduction in antibiotic prescribing appeared to increase the re-consultation rate but did not affect clinical recovery, resolution of symptoms, or hospital admissions. Limited evidence showed no significant effects of CRP-POCT on antibiotic prescribing at any point during 28 days of follow-up (n = 7) but less antibiotic prescribing at the index consultation in the GPs intervention sustained at 12 months (n = 1). The increased re-consultations and longer-term effects of CRP-POCT need further evaluation. The overall benefits of CRP-POCT (NNTnet = 11) on reducing antibiotic prescribing (NNTB = 8) outweigh the potential harms of increased re-consultations (NNTH = 27).

    The entry is from 10.3390/antibiotics9090610

    References

    1. Centers for Disease Control and Prevention. Measuring Outpatient Antibiotic Prescribing. 2020. Available online: https://www.cdc.gov/antibiotic-use/community/programs-measurement/measuring-antibiotic-prescribing.html (accessed on 10 June 2020).
    2. Fleming-Dutra, K.E.; Hersh, A.L.; Shapiro, D.J.; Bartoces, M.; Enns, E.A.; File, T.M., Jr.; Finkelstein, J.A.; Gerber, J.S.; Hyun, D.Y.; Linder, J.A.; et al. Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010–2011. JAMA 2016, 315, 1864–1873.
    3. Costelloe, C.; Metcalfe, C.; Lovering, A.; Mant, D.; Hay, A.D. Effect of antibiotic prescribing in primary care on antimicrobial resistance in individual patients: Systematic review and meta-analysis. BMJ 2010, 340, c2096.
    4. Goossens, H.; Ferech, M.; Vander Stichele, R.; Elseviers, M. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 2005, 365, 579–587.
    5. Cars, O.; Högberg, L.D.; Murray, M.; Nordberg, O.; Sivaraman, S.; Lundborg, C.S.; So, A.D.; Tomson, G. Meeting the challenge of antibiotic resistance. BMJ 2008, 337, a1438.
    6. Smith, S.M.; Fahey, T.; Smucny, J.; Becker, L.A. Antibiotics for acute bronchitis. Cochrane Database Syst. Rev. 2014, 3, CD000245.
    7. Little, P.; Stuart, B.; Moore, M.; Coenen, S.; Butler, C.C.; Godycki-Cwirko, M.; Mierzecki, A.; Chlabicz, S.; Torres, A.; Almirall, J.; et al. Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: A 12-country, randomised, placebo-controlled trial. Lancet Infect. Dis. 2013, 13, 123–129.
    8. Butler, C.C.; Hood, K.; Verheij, T.; Little, P.; Melbye, H.; Nuttall, J.; Kelly, M.J.; Molstad, S.; Godycki-Cwirko, M.; Almirall, J. Variation in antibiotic prescribing and its impact on recovery in patients with acute cough in primary care: Prospective study in 13 countries. BMJ 2009, 338, B2242.
    9. Lee, G.C.; Reveles, K.R.; Attridge, R.T.; Lawson, K.A.; Mansi, I.A.; Lewis, J.S.; Frei, C.R. Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med. 2014, 12, 96.
    10. European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). 2011. Available online: http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2011.pdf (accessed on 10 June 2020).
    11. Lode, H. Safety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infections. Am. J. Med. 2010, 123, S26–S38.
    12. Kollef, M.H. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: Getting it right up front. Clin. Infect. Dis. 2008, 47 (Suppl. 1), S3–S13.
    13. Chang, C.Y.; Schiano, T.D. Review article: Drug hepatotoxicity. Aliment Pharmacol. Ther. 2007, 25, 1135–1151.
    14. Little, P.; Gould, C.; Williamson, I.; Warner, G.; Gantley, M.; Kinmonth, A.L. Reattendance and complications in a randomised trial of prescribing strategies for sore throat: The medicalising effect of prescribing antibiotics. BMJ 1997, 315, 350–352.
    15. O’Neill, J. Review on Antimicrobial Resistance Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations; Review on Antimicrobial Resistance: London, UK, 2014; Available online: https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf (accessed on 10 June 2020).
    16. Tonkin-Crine, S.K.; Tan, P.S.; van Hecke, O.; Wang, K.; Roberts, N.W.; McCullough, A.; Hansen, M.P.; Butler, C.C.; Del Mar, C.B. Clinician-targeted interventions to influence antibiotic prescribing behaviour for acute respiratory infections in primary care: An overview of systematic reviews. Cochrane Database Syst. Rev. 2017, 9, CD012252.
    17. Brookes-Howell, L.; Hood, K.; Cooper, L.; Coenen, S.; Little, P.; Verheij, T.; Godycki-Cwirko, M.; Melbye, H.; Krawczyk, J.; Borras-Santos, A.; et al. Clinical influences on antibiotic prescribing decisions for lower respiratory tract infection: A nine country qualitative study of variation in care. BMJ Open 2012, 2.
    18. Van den Bruel, A.; Haj-Hassan, T.; Thompson, M.; Buntinx, F.; Mant, D. Diagnostic value of clinical features at presentation to identify serious infection in children in developed countries: A systematic review. Lancet 2010, 375, 834–845.
    19. Arnold, S.R.; To, T.; McIsaac, W.J.; Wang, E.E. Antibiotic prescribing for upper respiratory tract infection: The importance of diagnostic uncertainty. J. Pediatr. 2005, 146, 222–226.
    20. Teepe, J.; Broekhuizen, B.D.L.; Loens, K.; Lammens, C.; Ieven, M.; Goossens, H.; Little, P.; Butler, C.C.; Coenen, S.; Godycki-Cwirko, M.; et al. Predicting the presence of bacterial pathogens in the airways of primary care patients with acute cough. CMAJ 2017, 189, E50–E55.
    21. Falk, G.; Fahey, T. C-reactive protein and community-acquired pneumonia in ambulatory care: Systematic review of diagnostic accuracy studies. Fam. Pract. 2009, 26, 10–21.
    22. Woodhead, M.; Blasi, F.; Ewig, S.; Garau, J.; Huchon, G.; Ieven, M.; Ortqvist, A.; Schaberg, T.; Torres, A.; van der Heijden, G.; et al. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect. 2011, 17 (Suppl. 6), E1–E59.
    23. National Institute for Health and Care Excellence (NICE). Pneumonia: Diagnosis and Management of Community- and Hospital-Acquired Pneumonia in Adults; NICE: London, UK, 2014.
    24. Aabenhus, R.; Jensen, J.U.; Jorgensen, K.J.; Hrobjartsson, A.; Bjerrum, L. Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care. Cochrane Database Syst. Rev. 2014, 11, CD010130.
    25. Verbakel, J.Y.; Lee, J.J.; Goyder, C.; Tan, P.S.; Ananthakumar, T.; Turner, P.J.; Hayward, G.; Van den Bruel, A. Impact of point-of-care C reactive protein in ambulatory care: A systematic review and meta-analysis. BMJ Open 2019, 9, e025036.
    More
    1. Please check and comment entries here.